Key result
Point-of-care ultrasound (POCUS) is an accurate and accessible screening tool for valvular heart disease, but large-scale data on its efficacy and cost-effectiveness are currently lacking.
Why the study?
Valvular heart disease is increasing due to an aging population, yet most patients with severe disease remain undiagnosed.
Can point-of-care ultrasound (POCUS) serve as an effective screening tool for valvular heart disease?
Can point-of-care ultrasound (POCUS) serve as an effective screening tool for valvular heart disease?
POCUS shows promise as an accessible screening tool for valvular heart disease, but widespread implementation requires standardized protocols and large-scale validation.
May inform targeted valvular screening now; leaves open large-scale efficacy and cost-effectiveness questions.
BACKGROUND: A linear increase in the number of valvular heart disease is expected due to the aging population, yet most patients with severe valvular heart disease remain undiagnosed. HYPOTHESIS: POCUS can serve as a screening tool for valvular heart disease. METHODS: We reviewed the literature to assess the strengths and limitations of POCUS in screening and diagnosing valvular heart disease. RESULTS: POCUS is an accurate, affordable, accessible, and comprehensive tool. It has a fast learning curve and can prevent unnecessary and more expensive imaging. Challenges include training availability, lack of simplified screening protocols, and reimbursement. Large scale valvular screening data utilizing POCUS is not available. CONCLUSION: POCUS can serve as a screening tool and guide the management of patients with valvular heart disease. More data is needed about its efficacy and cost-effectiveness in the screening of patients with valvular heart disease.
No takes yet. Share an insight, caveat, or question.
Hammadah et al. (2020) conducted a review in Valvular heart disease. Point-of-care ultrasound (POCUS) was evaluated. Point-of-care ultrasound (POCUS) is an accurate and accessible screening tool for valvular heart disease, but large-scale data on its efficacy and cost-effectiveness are currently lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: